Philip Morris International (PM) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is a moderate beat on adjusted EPS with the bar reset lower by the June 2 currency/impairment guidance revision, but the real debate is whether ZYN U.S. offtake is re-accelerating and whether international smoke-free can sustain its Q1 momentum through Japan’s pantry de-loading headwind — those two variables, not EPS arithmetic, will drive the stock.

Heading into Q2 2026 results, the consensus adjusted diluted EPS estimate of ~$2.04 sits below the $2.02–$2.07 guidance range PM issued on April 22 and was subsequently revised to $1.97–$2.02 at the June 2 Deutsche Bank conference to reflect an unfavorable currency impact from unrealized transactional FX effects tied to deferred tax liabilities on the strengthening Russian ruble — a non-cash, non-operational item that management explicitly flagged as the sole driver of the revision, leaving all organic assumptions intact. International smoke-free is the engine: Q1 delivered double-digit HTU volume growth, mid-teens organic revenue growth, and high-teens organic gross profit growth, and management guided for “continued strong performance” in Q2 with mid-single-digit organic net revenue growth and solid operating income progression despite another quarter of heavy commercial investment. The primary headwind is Japan, where the April 1 excise-driven price increase triggered consumer pantry de-loading that management expects to weigh on Q2 adjusted IMS growth — a known, transitory dynamic that is broadly in line with internal expectations. On the U.S. side, ZYN Ultra launched in June 2026 in 9mg and 11mg moist variants at a lower per-pouch price point, directly addressing the portfolio gap and price premium that has pressured ZYN’s share over the past several quarters; the key question is whether early shipment data signals a meaningful offtake inflection or merely a channel fill. The stock has rallied ~15% since Q1 earnings (indexed basis), outperforming XLP (+2%) and the S&P 500 (+5%), suggesting the market has already priced in a solid print — the bar for a positive reaction is therefore higher than the EPS number alone implies. The wildcard is the EU tobacco excise directive outcome, which management expected to be resolved by end of Q2 and could provide a meaningful regulatory tailwind or headwind for the international smoke-free growth algorithm.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sits at the low end of PM’s own Q2 guidance range on adjusted EPS ($2.04 vs. $1.97–$2.02 revised guidance), suggesting the bar is achievable; the bigger swing factor is ZYN U.S. can volume (consensus ~189M cans vs. ~180M underlying base) and whether HTU shipments (consensus ~41.3B units) hold up through Japan’s pantry de-loading reversal.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha consensus and actuals data. Q2 2026 guidance from PM Q1 2026 earnings call (April 22, 2026) and Deutsche Bank Global Consumer Conference press release (June 2, 2026). ZYN underlying Q2 base per management guidance on Q1 2026 earnings call (~180M cans).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs)

Adjusted Diluted EPS

ZYN U.S. Cans (M cans)

Pattern: PM has beaten adjusted EPS consensus in each of the last 8 quarters, with surprise magnitudes ranging from +2.4% to +6.2%, establishing a consistent track record of conservative guidance and execution. ZYN U.S. can volumes missed sharply in Q1 2026 due to inventory normalization, but the underlying offtake base was ~10% higher than reported shipments; historical consensus data for ZYN cans is not available in Visible Alpha for prior quarters. Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been revised once since Q1 earnings — at the June 2 Deutsche Bank conference, PM lowered its Q2 adjusted EPS range by ~$0.05 and its FY2026 adjusted EPS range by ~$0.05 solely for currency (Russian ruble transactional FX on deferred tax liabilities) and a non-cash RBH impairment charge; all organic assumptions remain unchanged, and management explicitly reaffirmed the full-year organic growth algorithm.

Source: PM Q1 2026 Earnings Call transcript (April 22, 2026); PM Deutsche Bank Global Consumer Conference transcript and press release (June 2, 2026); Visible Alpha consensus data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 EPS have drifted ~6% lower since Q1 earnings, tracking the June 2 guidance revision; FY2026 EPS estimates have similarly declined ~1.4%, but remain within the revised guidance range — the gap between consensus and guidance midpoint is narrow, suggesting limited cushion for further downward revision but also limited upside surprise from estimate drift alone.

Estimates have tracked guidance revisions closely, with EPS estimates declining modestly post the June 2 guidance update. The narrow gap between current consensus and the revised guidance midpoint (+2% for Q2 EPS) suggests the street has largely absorbed the currency revision; any organic upside — particularly from ZYN Ultra early shipment data or stronger-than-expected Japan IQOS share retention — would represent incremental upside to current numbers. Source: Visible Alpha consensus and actuals data; PM Q1 2026 Earnings Call (April 22, 2026); PM Deutsche Bank Global Consumer Conference (June 2, 2026).

5. Stock Performance

Key Takeaway: PM has rallied ~15% since Q1 earnings (April 22, 2026), dramatically outperforming XLP (+2%) and the S&P 500 (+5%), driven almost entirely by multiple expansion (P/E NTM expanded from ~20.8x to ~23.3x over 6 months) rather than estimate revisions — the stock is pricing in successful transformation execution, raising the bar for a positive reaction on Q2 results.

The chart below shows PM, XLP (Consumer Staples ETF), and S&P 500 indexed to 100 at the Q1 2026 earnings date (April 22, 2026). PM’s outperformance accelerated sharply in mid-May following the ZYN Ultra launch announcement and FDA enforcement priorities guidance, which the market interpreted as a regulatory tailwind for the nicotine pouch category. The June 2 guidance revision (currency/RBH impairment) caused a brief pullback but was quickly absorbed. PM’s 3-month return of +19.4% compares to XLP flat and S&P 500 +5.2%, with multiple expansion accounting for the majority of the move (EV/EBITDA expanded from ~14.5x to ~17.1x over 3 months). Source: Stock Price Data (Yahoo Finance); PM Stock Performance Decomposition data.

PM vs. XLP vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (April 22, 2026). Vertical dashed line marks June 2, 2026 guidance update at Deutsche Bank conference. Source: Yahoo Finance.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the June 2026 launch of ZYN Ultra (9mg/11mg moist variants, 20-pouch can, lower per-pouch price), which directly addresses the portfolio gap and price premium that has pressured ZYN’s U.S. market share — early shipment data from this launch will be the single most watched data point on the Q2 call.

• June 2026 — ZYN Ultra Launch (9mg & 11mg moist variants, 20-pouch can format). PM commenced shipments of ZYN Ultra in June 2026, priced at a lower list price-per-pouch than the flagship dry ZYN 15-pouch format (equivalent to ~16 pouches per can pricing). This directly addresses ZYN’s ~60–70% retail price premium vs. competition, which management acknowledged has been a source of share pressure. Further ZYN extensions are planned for H2 2026.
• June 2, 2026 — Deutsche Bank Conference: Guidance Revision (Currency/RBH Only). PM revised Q2 2026 adjusted EPS guidance to $1.97–$2.02 (from $2.02–$2.07) and FY2026 adjusted EPS to $8.31–$8.46 (from $8.36–$8.51), solely reflecting: (1) ~$0.03 unfavorable currency impact from unrealized transactional FX on deferred tax liabilities tied to the strengthening Russian ruble, and (2) a ~$500M (~$0.33/share) non-cash impairment of PM’s investment in RBH (Canadian affiliate, deconsolidated). All organic assumptions unchanged. Management reaffirmed “the whole underlying view for the year remains intact.”
• July 9, 2026 — CFO Transition: Emmanuel Babeau Separation. PM filed an 8-K detailing CFO Emmanuel Babeau’s separation terms. A new CFO compensation package (Andolina) was detailed in a June 16, 2026 8-K/A. Leadership transitions at the CFO level introduce modest execution risk but are unlikely to alter the strategic trajectory given CEO Jacek Olczak’s continued leadership.
• June 29, 2026 — €1 Billion Term Loan Prepayment. PM prepaid €1 billion of its term loan facility, accelerating deleveraging toward the 2x net debt/EBITDA target management has committed to reaching by year-end. This is a positive signal for buyback resumption timing.
• April 29, 2026 — $1.5 Billion Debt Offering. PM completed a $1.5B debt offering, consistent with ongoing balance sheet management and refinancing activity.
• May 2026 — FDA Enforcement Priorities Guidance for Nicotine Pouches. The FDA published enforcement priorities guidance for unauthorized nicotine pouch products with pending applications, enabling ZYN Ultra shipments to commence. Management characterized this as a “net positive” and a convergence of FDA and PMI views on market evolution. BAT similarly welcomed the guidance as “an important step toward effective enforcement and expanding market access for responsible industry players.”
• Q1 2026 — FDA Reauthorizes Previous IQOS Version as MRTP. The FDA reauthorized the previous version of IQOS as a Modified Risk Tobacco Product. Management continues to engage FDA on IQOS ILUMA authorization and expressed confidence that U.S. IQOS launch is “very close.”
• April 2026 — France Bans Nicotine Pouches. France enacted a ban on nicotine pouches (including possession and use, with penalties up to five years in prison). Management characterized it as “simply stupid” regulation and a temporary setback, expressing confidence that sensible regulation will prevail. Implication: modest near-term headwind to European smoke-free revenue, but France is not a primary ZYN market.
• Q2 2026 — EU Tobacco Excise Directive Negotiations. Management expected the EU tobacco excise directive outcome within weeks of the June 2 conference. The result (not yet public as of this writing) could be a meaningful regulatory catalyst for the international smoke-free growth algorithm.
• May 2026 — ZYN by IQOS Expanding in Japan. PM commenced expansion of ZYN by IQOS in Tokyo from May 2026 through IQOS stores and convenience retailers, leveraging the IQOS brand infrastructure to accelerate pouch adoption in a new market.

7. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by PM insiders in the last 60 days; the only Form 4 activity was routine annual director equity grants (transaction code “A” — award/grant) on May 6, 2026, which carry no informational signal regarding management’s view of the stock.

All transactions are equity grants (Form 4 code “A” — Award/Grant), not open-market purchases or sales. No discretionary open-market buys or sells were filed in the last 60 days. The absence of insider selling ahead of earnings is a mild positive, but the absence of open-market buying is also notable given the stock’s strong run. Source: SEC Form 4 filings database.

8. Peer Commentary — Current-Quarter Read-Throughs (Last 60 Days)

Key Takeaway: The most actionable peer read-through comes from BAT’s June 2, 2026 Q2 pre-close call, which confirms: (1) the U.S. nicotine pouch category is growing strongly with Velo Plus gaining share rapidly at PM’s expense, validating the competitive pressure PM has acknowledged; (2) Japan heated tobacco inventory de-stocking is a real, material headwind for BAT’s Glo (low double-digit revenue decline), providing a directional read on the magnitude of Japan’s impact on PM’s Q2 HTU IMS; and (3) FDA enforcement priorities guidance is broadly positive for all compliant players. No qualifying current-quarter commentary was identified from Altria (MO) or Imperial Brands (IMB) within the screening window.

Screening Criteria: Included only peer commentary published in the last 60 days (on or after May 22, 2026) that addresses the peer’s current reporting period (Q2 2026 / H1 2026) or forward current-quarter conditions. Excluded: historical-period earnings call commentary about prior quarters’ results (e.g., MO’s April 30 Q1 2026 earnings call discussing Q1 results is excluded as it addresses a completed period, not the current Q2 reporting quarter). Peers screened: BAT (BATS LN), Altria (MO), Imperial Brands (IMB LN), Japan Tobacco (not in coverage universe).

BAT (BATS LN) — Q2 2026 Pre-Close Conference Call, June 2, 2026

Relevance: BAT’s Q2 pre-close call is the single most relevant peer read-through for PM’s Q2 print. BAT competes directly with PM in heated tobacco (Glo vs. IQOS), nicotine pouches (Velo/Velo Plus vs. ZYN), and combustibles across overlapping international markets. The call addressed H1 2026 and full-year 2026 conditions — the current reporting period — making it fully qualifying under the screening criteria.

Read-Through 1: U.S. Nicotine Pouch Category — Competitive Pressure on ZYN Confirmed

BAT reported that Velo Plus has gained 740 basis points of volume share year-to-date to reach 38.2% across top modern oral markets in the U.S., with Velo Plus described as “the fastest growing modern oral brand” and capturing “100% of category value growth year to date.” Velo Plus has achieved category share leadership in seven states. BAT expects “strong double-digit revenue growth” in U.S. modern oral for the full year. The Velo Plus price index has risen from 65% to 90–95% of the leading brand (ZYN), narrowing the gap between volume share (28%) and value share (23%).

PM Read-Through: This directly validates PM’s own commentary that ZYN has been under “market share pressure over the last few quarters” due to portfolio asymmetry and price premium. BAT’s aggressive share gains at a rising price index confirm that the competitive dynamic is intensifying, not abating. The ZYN Ultra launch (lower per-pouch price, moist format) is PM’s direct response. The category itself is growing ~25% YoY (per PM’s Q1 call), so ZYN can still grow in absolute terms even while losing share — but the share trajectory is a key watch item. BAT also noted U.S. average daily consumption of 3.6 pouches/day vs. 8–12 in the Nordics, underscoring the long-term category growth runway that benefits PM’s ZYN franchise.

Read-Through 2: Japan Heated Tobacco — Inventory De-Stocking Is a Real, Material Headwind

BAT guided that its heated tobacco segment (Glo) would see H1 and full-year revenue down low double digits, with the “major driver” being “adjustment in stocks in the main distributor in Japan” following the April 1 excise-driven price increase. BAT described this as a “one-off” that will “carry on throughout the year” (i.e., no H2 rebound from the inventory de-stocking itself). BAT also noted “continued competitive intensity in the value segment” as a secondary headwind. Glo’s volume share in Japan was “down 2.1 percentage points” in APMEA.

PM Read-Through: This is a highly relevant directional read for PM’s Q2 HTU IMS growth in Japan. PM guided for “slower HTU adjusted IMS growth due to the short-term impact of excise-driven pricing in Japan” in Q2, and the Q1 call noted that Q2 adjusted IMS growth would “reflect the reversal of consumer pantry-loading and the price increases which took effect on April 1.” BAT’s experience with Glo — low double-digit revenue decline driven by Japan inventory de-stocking — suggests the Japan headwind is real and material, though PM’s IQOS has a far stronger market position (IQOS holds ~75% of the heat-not-burn category vs. Glo’s much smaller share) and may experience a less severe impact. The key distinction: PM’s Q1 call noted IQOS share in Japan is “plus/minus intact,” while BAT’s Glo lost 2.1 points of APMEA share. This suggests PM is better positioned to weather the Japan excise headwind than BAT.

Read-Through 3: FDA Enforcement Priorities Guidance — Broadly Positive for Compliant Players

BAT “welcomed the FDA’s recently published prioritization guidance as an important step toward effective enforcement and expanding market access for responsible industry players,” noting it provides “a clear and consistent pathway for scientifically substantiated, less risky products to reach the market.” BAT sees “a clear pathway to marketing authorizations for our leading higher moisture products” and noted that the FDA’s Center for Tobacco Products intends to use learnings from the modern oral pilot program to “inform a broader, applicable approach to expedite a review beyond the modern oral category.”

PM Read-Through: Consistent with PM’s own characterization of the FDA guidance as a “net positive.” The FDA’s stated intent to expedite reviews beyond the modern oral category is a direct positive signal for PM’s IQOS ILUMA authorization process. Both companies are aligned that the FDA’s enforcement approach — by creating a regulated pathway for legitimate products — reduces the oxygen available for illicit market participants, which is particularly relevant for the vape category where PM’s VEEV competes.

Read-Through 4: U.S. Combustibles — Industry Decline Moderating, Deep Discount Pressure Persists

BAT reported that the pace of U.S. industry combustibles decline has “moderated down by around 5% year to date on a sales to retail basis, mainly driven by deep discount brands.” BAT’s own U.S. combustibles performance is expected to be “first half weighted” as it laps a stronger prior year comparator in H2. BAT noted “intense competitive activity” in Q4 2025 and has been expanding its Doral deep-discount brand in additional states.

PM Read-Through: PM does not have a U.S. combustibles business (IQOS is not yet commercially launched in the U.S.), so the direct read-through is limited. However, the moderation in U.S. industry combustibles decline is a mild positive for the overall nicotine market backdrop. The deep discount segment growth is more relevant to Altria (MO) than PM.

Read-Through 5: New Category Revenue Acceleration — Positive Industry Backdrop

BAT guided for new category revenue growth to “accelerate to mid-teens in H1 and for the full year,” driven by modern oral across all three regions, a return to growth in vapor, and continued innovation traction. BAT expects “further improvement in new category contribution driven by modern oral and vapor.”

PM Read-Through: The acceleration of new category revenue growth at BAT is a positive read-through for the broader smoke-free industry backdrop. PM’s international smoke-free business (IQOS + ZYN international + VEEV) is the primary driver of its growth algorithm, and BAT’s commentary confirms that consumer demand for reduced-risk products remains robust across geographies. The mid-teens new category revenue growth at BAT is directionally consistent with PM’s own mid-teens organic smoke-free revenue growth trajectory.

Altria (MO) — No Qualifying Current-Quarter Commentary Identified

Altria reported Q1 2026 results on April 30, 2026 and reaffirmed full-year guidance. However, the April 30 earnings call addressed Q1 2026 results (a completed period) and is therefore excluded under the screening criteria. No Altria conference presentations, investor day transcripts, or 8-K pre-announcements addressing Q2 2026 / current-quarter conditions were identified in the last 60 days (on or after May 22, 2026). Altria’s most recent qualifying commentary would be its Q1 2026 earnings call, which is outside the current-quarter screening window. No qualifying MO peer commentary included.

Imperial Brands (IMB LN) — No Qualifying Current-Quarter Commentary Identified

No Imperial Brands conference presentations, investor day transcripts, or pre-announcements addressing current-quarter (Q2 2026 / H1 2026) conditions were identified in the last 60 days. Imperial Brands’ fiscal year ends September 30, and its most recent earnings event was its H1 FY2026 results (period ending March 31, 2026), which falls outside the current-quarter screening window. No qualifying IMB peer commentary included.

Peer Read-Through Summary Table

Source: BAT Q2 2026 Pre-Close Conference Call transcript (June 2, 2026). MO and IMB excluded per screening criteria — no qualifying current-quarter commentary identified within the last 60 days.